Acute rhabdomyolysis during the treatment of scleromyxedema with interferon alfa

A 34-year-old white man developed acute rhabdomyolysis during the treatment of scleromyxedema with interferon alfa. If interferon alfa is to be used as a therapeutic option for scleromyxedema the possibility of rhabdomyolysis should be considered. To the best of our knowledge, this is the first case...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of dermatological treatment 2001, Vol.12 (3), p.167-169
Main Author: Ozdag, A Akar, E Eroglu, H Erbil, F
Format: Article
Language:English
Subjects:
Acute Disease
Adult
Biological and medical sciences
Drug toxicity and drugs side effects treatment
Humans
Interferon-alpha - adverse effects
Interferons Lichen Myxedematosus Papular Mucinosis Rhabdomyolysis Scleromyxedema
Lichenoid Eruptions - drug therapy
Male
Medical sciences
Mucinoses - drug therapy
Myxedema - drug therapy
Pharmacology. Drug treatments
Rhabdomyolysis - chemically induced
Toxicity: nervous system and muscle
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A 34-year-old white man developed acute rhabdomyolysis during the treatment of scleromyxedema with interferon alfa. If interferon alfa is to be used as a therapeutic option for scleromyxedema the possibility of rhabdomyolysis should be considered. To the best of our knowledge, this is the first case in which acute rhabdomyolysis was developed during the treatment of scleromyxedema with interferon alfa.
ISSN:0954-6634
1471-1753
DOI:10.1080/09546630152607916